Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol

Excerpt from the Press Release:

SOLANA BEACH, Calif., March 02, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that the Company received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/835,383 entitled “Solid Forms of Cannabidiol and Uses Thereof” related to its ART12.11 program, a cocrystal composition of cannabidiol (CBD). In addition, the Company has pending foreign patent applications covering cocrystal composition-of-matter and method of use.

“The method of use claims of this patent combined with the CBD cocrystal’s composition of matter patent already issued in the US further enhances our overall intellectual property portfolio,” stated Gregory D. Gorgas, President and CEO of Artelo Biosciences. “Our strategy is to leverage the strength of our science and patents to develop important advancements in the treatment of serious conditions, such as PTSD and cancer, as we target large and underserved markets where we believe our patent portfolio provides a distinct competitive advantage.”

This patent claims methods for treating a disease or condition selected from central nervous system disorders, cardiovascular disorders, neurovascular disorders, neuromuscular disorders, cancers, autoimmune disorders, inflammation, pain, sleep disorders, posttraumatic stress disorder, posttraumatic stress syndrome; nausea, and hypoxia-ischemia. It is expected this patent will have a patent term until 2038, not including any possible patent term extensions.

About ART12.11
ART12.11 is a proprietary cocrystal composition of cannabidiol (CBD). The crystal structure of CBD is known to exhibit solid polymorphism, or the ability to manifest in different forms. Artelo believes its cocrystal exists as a single crystal form and, as such, is anticipated to have advantages over other solid forms of CBD that exhibit polymorphism. Anticipated advantages of this single crystal structure include improved stability, solubility, and a more consistent absorption profile. Artelo believes these features will result in more consistent and improved bioavailability and may ultimately lead to improved safety and efficacy.

Click the button below to read the entire Press Release:

Continue Reading The Press Release